Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Are remissions for AML patients 'better' after daunorubicin and cytarabine liposome injection

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 24.12.19
Views: 234
Rating:

Prof Daniel Ryan - University of Rochester, Rochester, USA

Prof Daniel Ryan speaks to ecancer at the ASH 2019 meeting in Orlando about the quality of remission after daunorubicin and cytarabine liposome injection.

He outlines the parent study and results, before explaining this subgroup analysis and results.

Related videos

follow us

Donate to ecancer


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation